In the first week of August 2026, UK media reported figures drawn from the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme showing hundreds of suspected deaths and tens of thousands of serious reactions reported against GLP-1 receptor agonists used for weight management. The stories are a reminder of how quickly spontaneous-reporting totals can be read as confirmed harm — and why the MHRA's own caveats matter.

What the Yellow Card scheme records

The Yellow Card scheme is the UK system for collecting reports of suspected adverse drug reactions. Reports can be submitted by healthcare professionals, patients, carers and members of the public, as well as by pharmaceutical companies. Its purpose is signal detection: to identify patterns that may warrant further investigation. A Yellow Card report records that someone suspected a possible link between a medicine and an event; it is not a finding that the medicine caused it.

The figures as reported

As reported in early August 2026, cumulative Yellow Card totals for the three GLP-1 medicines most used in the UK weight-management market were:

  • Tirzepatide (Mounjaro): 120 suspected-link death reports among about 106,000 adverse-reaction reports, roughly 11,500 of them classed as serious.
  • Semaglutide (Wegovy): 59 suspected-link death reports among about 48,000 reports, around 5,700 serious.
  • Liraglutide (Saxenda): 37 suspected-link death reports among about 4,500 reports, around 1,100 serious.

That gives 216 suspected-link death reports across the three and roughly 159,000 total adverse-reaction reports. Headline figures varied between outlets — The Times reported about 150,000 reports and more than 100 deaths, The Independent more than 150 deaths, and Sky News more than 200 — because different reports used different cut-offs and reporting dates. These are cumulative totals since each medicine entered wider UK use, not a single-year count.

Why a report is not a confirmed cause

The MHRA states explicitly that a Yellow Card report reflects the reporter's suspicion of a possible link, not a confirmed causal finding. Underlying illness, other medicines and coincidence can all explain an event, and the same case can be reported more than once by different people. Report counts are therefore not equivalent to confirmed fatality counts. The totals must also be read against the size of the exposed population: millions of prescriptions have been issued in the UK, so the reports represent a small fraction of use — which does not make them unimportant, only patient.

At least two individual UK cases have been examined more closely. Susan McGowan, a 58-year-old nurse from North Lanarkshire, died in September 2024; her death certificate listed multiple organ failure, septic shock and pancreatitis as the immediate cause, with prescribed tirzepatide recorded as a contributing factor. In July 2026 a coroner concluded that a GLP-1 agonist had contributed to the death of Paula Owen, aged 66, in Plymouth, from acute pancreatitis. These are findings in individual inquests, not class-wide determinations of causality.

The pancreatitis signal

The pancreatitis reports are the clearest signal in the data, and the one the MHRA has already acted on. In a Drug Safety Update dated 29 January 2026, the MHRA strengthened warnings across all GLP-1 and dual GIP/GLP-1 receptor agonists to highlight the potential risk of severe acute pancreatitis, including rare reports of necrotising and fatal cases. The regulator noted nearly 400 UK reports of acute or chronic pancreatitis associated with GLP-1 therapies and advises healthcare professionals to remain vigilant for the signs. A separate Yellow Card Biobank study is examining whether genetic factors influence pancreatitis risk with these medicines.

The UK regulatory backdrop

In the UK, GLP-1 receptor agonists are prescription-only medicines. Supply, labelling and advertising are governed by the Medicines Act 1968 and the Human Medicines Regulations 2012, and the MHRA has repeatedly reminded suppliers that these products cannot lawfully be sold for weight management outside the prescription framework. The same enforcement logic covers research peptides sold with a 'research use only' label that are, in substance, offered for human use.

What researchers should take from it

For anyone tracking the peptide field, three points are worth holding together. First, a spontaneous-reporting total is a signal-generation tool, not an incidence measure; the serious and fatal counts cannot be converted directly into a risk per user. Second, the pancreatitis signal is the one with regulatory action behind it, and it applies across the class rather than to a single product. Third, the figures underline why Peptide Data frames all content in a research-use-only context: these are licensed prescription medicines with documented safety signals and a formal reporting system behind them, whereas research peptides have no comparable human safety database at all.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.